Limertinib is a newly developed small-molecule chemical drug, specifically designed as an inhibitor targeting the epidermal growth factor receptor (EGFR) T790M mutation.
Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.
Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.